CD274 and neoplasm: Other ongoing clinical trials are investigating the use of drugs against other ME components as main targets; these include tumor (T)ME physical barriers (extracellular matrix, fibroblast activating protein collagen, and laminin), immune checkpoints such as CTLA-4 and PD-1/PD-L1, MDSCs, immunosuppressive macrophages, Tregs, inhibitory cytokines, and metabolic inhibition signaling [207].